GameSquare's Stream Hatchet Publishes 2025 Q2 Live Streaming Trends Report
FRISCO, TEXAS / ACCESS Newswire / July 30, 2025 / Stream Hatchet, the leading provider of data analytics for the live streaming and gaming ecosystem and wholly-owned subsidiary of GameSquare Holdings (NASDAQ:GAME), ('GameSquare', or the 'Company'), has released its Q2 2025 Live Streaming Trends Report. The report reveals key insights into the evolution of the global live streaming market across gaming, esports, and entertainment.
Access to the report is available at: https://www.streamhatchet.com/reports/q2-2025-live-streaming-trends
'The Q2 2025 report from Stream Hatchet underscores the continued growth of live streaming as a dominant force in media consumption,' said Justin Kenna, CEO of GameSquare. 'These insights highlight how audiences are shifting toward interactive, creator-led content experiences that offer greater engagement than traditional formats.'
Key Insights from Stream Hatchet's 2025 Q2 Report:
9.1 billion hours watched in 2025 Q2, reflecting the highest quarterly level since 2021
Live streaming viewership continues to grow, up 5% year-on-year, surpassing the 9 billion mark for the first time since 2021
YouTube Gaming recorded its highest ever quarterly viewership at 2.2 billion hours watched Twitch's market share continues to decline, down 4.6% in 2025 Q2 to 54%
YouTube Gaming holds onto just under a quarter of the market share
Kick continues to grow, with their market share up 5.5% to almost 11% of the streaming market
Despite 37% fewer tournaments compared to 2024 Q2, esports tournaments recorded a 6% increase in viewership to 729 million hours watched
Viewership was evenly split between co-streaming channels and official esports channels, highlighting audiences growing preference for creator-driven content
For more information on Stream Hatchet and insight into the esports and streaming markets, please visit their website at www.streamhatchet.com.
About GameSquare Holdings, Inc.
GameSquare (NASDAQ: GAME) is a cutting-edge media, entertainment, and technology company transforming how brands and publishers connect with Gen Z, Gen Alpha, and Millennial audiences. With a platform that spans award-winning creative services, advanced analytics, and FaZe Clan, one of the most iconic gaming organizations, we operate one of the largest gaming media networks in North America. Complementing our operating strategy, GameSquare operates a blockchain-native Ethereum treasury management program designed to generate onchain yield and enhance capital efficiency, reinforcing our commitment to building a dynamic, high-performing media company at the intersection of culture, technology, and next-generation financial innovation.
To learn more, visit www.gamesquare.com.
About Stream Hatchet
Stream Hatchet delivers real-time, actionable insights into the gaming and live-streaming ecosystem across 16 platforms. From performance benchmarking to campaign ROI and influencer intelligence, Stream Hatchet empowers game publishers, brands, agencies, and tournament organizers with the industry's most granular data and reporting tools.
For more information visit www.streamhatchet.com .
Forward-Looking Information
This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Company's future performance, revenue, growth and profitability; and the performance of the live streaming market . These forward-looking statements are provided only to provide information currently available to us and are not intended to serve as and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Forward-looking statements are necessarily based upon a number of estimates and assumptions which include, but are not limited to: the Company's ability to grow their business and being able to execute on their business plans, the Company being able to complete and successfully integrate acquisitions, the Company being able to recognize and capitalize on opportunities and the Company continuing to attract qualified personnel to supports its development requirements. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company's ability to achieve its objectives, the Company successfully executing its growth strategy, the ability of the Company to obtain future financings or complete offerings on acceptable terms, failure to leverage the Company's portfolio across entertainment and media platforms, dependence on the Company's key personnel and general business, economic, competitive, political and social uncertainties. These risk factors are not intended to represent a complete list of the factors that could affect the Company which are discussed in the Company's most recent MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. GameSquare assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Corporate Contact
Lou Schwartz, President
Phone: (216) 464-6400
Email: ir@gamesquare.com
Investor Relations
Andrew Berger
Phone: (216) 464-6400
Email: ir@gamesquare.com
Media Relations
Chelsey Northern / The Untold
Phone: (254) 855-4028
Email: pr@gamesquare.com
SOURCE: GameSquare Holdings, Inc.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
First Solar Stock Jumps After Q2 Beat and Raised Full-Year Outlook
Aug 1 - First Solar (NASDAQ:FSLR) gained 6.5% on Friday afternoon after posting second?quarter results that topped Wall Street expectations and prompted the solar manufacturer to raise its full?year guidance. Warning! GuruFocus has detected 5 Warning Signs with FSLR. The company reported Q2 net income of $341.9 million, or $3.18 per share, compared with $349.4 million, or $3.25 per share, a year ago. Analysts surveyed by FactSet expected $2.66 per share. Revenue climbed to $1.1 billion from $1.01 billion a year earlier, driven by higher sales of solar modules to third?party customers. Management now projects 2025 revenue between $4.9 billion and $5.7 billion, up from a prior $4.5 billion to $5.5 billion. Earnings guidance tightened to $13.50$16.50 per share, versus the earlier $12.50$17.50 range. First Solar also raised the lower end of its full?year solar module shipment target to 16.719.3 GW and adjusted its gross margin outlook to $2.05$2.35 billion. CEO Mark Widmar said the company benefits from President Trump's recently enacted tax law, which favors U.S.?made solar panels while limiting credits tied to Chinese supply chains. Analysts note that ongoing trade and tariff uncertainty still poses challenges but may also create opportunities for domestic manufacturers. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Moderna Cuts Forecast, Stock Wobbles Despite Beat
Moderna's (NASDAQ:MRNA) quarter was okay on the numbers, but the stock slid because the company pulled back its full-year revenue outlook after delaying some U.K. vaccine shipments into early 2026. Q2 revenue was $142Million, down 41% from a year ago, with COVID shot sales at $114Million and its RSV vaccine barely registering. That pushed the 2025 revenue range to $1.5Billion$2.2Billion, about $300Million less than before. Warning! GuruFocus has detected 2 Warning Sign with MRNA. The good part is they've been cutting costs aggressively. OpEx is now guided to $5.9Billion$6.1Billion roughly $400Million lighter than prior expectationsand that helped trim the loss to about $800Million. Moderna still has a strong cash cushion: $7.5Billion at the end of June and roughly $6Billion expected at year-end, so the balance sheet isn't stressed. The delayed shipments rattled sentiment, but the company isn't burning cash. Now it comes down to executionU.K. deliveries must land as rescheduled and new revenue drivers need to show up before investors lose patience. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
20 minutes ago
- Business Wire
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last patient, last visit in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). Topline results from the study are expected in the fourth quarter of 2025. The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukapheresis for use in ASCT. In data presented at ASH 2024, GPC-100 appears to be well differentiated in terms of the speed with which it mobilizes stem cells compared to currently approved stem cell mobilization treatments. Dr. Muthalagu Ramanathan, Director of the Myeloma Program and Medical Co-Director of the Blood and Marrow Transplant and CAR-T Program at U Mass Memorial Health noted that 'traditionally, patients undergoing mobilization are required to come, as an outpatient, the night before their procedure to receive the mobilization injection — a process that adds logistical challenges. The study drug GPC100 needed to be administered just 45 minutes before stem cell collection and resulted in a successful mobilization, significantly improving the patient experience. This is a true blessing for our frail myeloma patients.' In addition to multiple myeloma and a planned Phase 1 study in acute myeloid leukemia (AML) patients, the company is also in discussions for potential collaborations that would utilize GPC-100's rapid and safe mobilization of stem cells in cell and gene therapy settings. About GPC-100 GPC-100 (burixafor) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, GPC-100 may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., GPC-100 became part of Exicure's pipeline following the company's acquisition in January 2025. In addition to multiple myeloma, GPC-100 is also being considered in acute myeloid leukemia (AML) and other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. About Exicure Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company's lead program, GPC-100, is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit
